Insect Écran's 50% DEET *Zones Infestées* spray was among the products ranked in the insect-repellent category of the 2026 'Meilleur Produit Pharma' consumer survey. The result is a useful signpost for how French pharmacy shoppers are choosing their repellents, and where that diverges from advice elsewhere in Europe, where icaridin at 20% has been the first-line pharmacy recommendation for the past decade.
In May 2026, the French consumer survey programme "Meilleur Produit Pharma" published its 2026 results. In the anti-insect category, one of the products ranked was a 50% DEET pocket spray, Insect Écran's Zones Infestées, marketed for "infested zones" and "particularly effective against the tiger mosquito", and claimed to deliver up to 16 hours of mosquito protection with two daily applications.
For anyone who has spent time inside the European repellent industry over the past five years, the headline is worth a small double-take. DEET at 50% remains a perfectly legal, fully approved, widely sold active ingredient in France. It is also the highest concentration that some other European pharmacy chains will routinely recommend to a customer, and a higher concentration than several public-health agencies elsewhere on the continent typically suggest as a first-line option. That a 50% DEET formulation still ranks in a 2026 consumer survey is not surprising in isolation. It is interesting in context.
What the 2026 Results Actually Show
The "Meilleur Produit Pharma" programme is a Biotopia-organised consumer survey, not a public-sector accreditation. A panel of 100 consumers rates the products across pharmacy categories, and the results carry a score out of 20. Zones Infestées was among the anti-insect products ranked.
The formulation, marketed by Coopération Pharmaceutique Française (Cooper) of Melun, contains 50% DEET (N,N-diethyl-meta-toluamide). Cooper states up to 8 hours of mosquito protection per application, and up to 7 hours against ticks; two applications give up to 16 hours against mosquitoes. The label specifically targets Aedes albopictus, the tiger mosquito, which is now established in 83 French metropolitan départements, and mainland France recorded 809 autochthonous chikungunya cases in 2025.
The product is sold mainly through pharmacies, and also online. The label carries the standard French biocidal warning, "Utilisez les biocides avec précaution" (use biocides with care), and it comes in 50 ml and 100 ml formats.
Why French Pharmacy Shoppers Are Reaching for High DEET
Several reasons line up.
The French market has lived with established Aedes albopictus longer than most of its neighbours. The tiger mosquito was detected in metropolitan France in 2004 and has been spreading north and west ever since. Mainland France's autochthonous chikungunya cases rose from a single case in 2024 to 809 in 2025. French pharmacists are now routinely answering questions from customers about transmission, not theoretical risk. In that setting, the highest-concentration repellent on the shelf carries an obvious allure: it lasts longer, it works against the species the customer is anxious about, and the prescriber feels covered.
There is also a pharmacy-channel structural reason. Insect Écran is a Cooper brand, marketed mainly through pharmacies rather than supermarkets. That channel skews toward customers who are willing to pay a premium for a recommendation from a professional, and the professional rewards the customer with a strong, specific product. The 50% DEET formulation fits the channel logic: a clear, decisive answer to a clear, decisive question.
And the 16-hour-with-two-applications claim sits at the upper end of what manufacturers say their formulations achieve. But on the box, "up to 16 hours" reads as decisive.
Why the European Drift Is the Other Way
The two actives answer different needs: icaridin (picaridin) as the general, family-friendly option, and DEET for higher-risk travel use or specifically high-pressure environments. This is not a regulatory ban. The US CDC names picaridin among the EPA-registered actives that are proven safe and effective when used as directed. Three things sit behind the difference:
The first is that icaridin is an effective alternative to DEET for general-use protection, and the US CDC names it among the EPA-registered actives that are proven safe and effective.
The second is paediatric advice. ANSES advises that repellents containing DEET, IR3535 or icaridin, where they hold a marketing authorisation, are effective and safe when used as directed, and that products differ mainly in the concentration of the active ingredient. Some are not permitted for children under two, and an adult must apply any repellent for a child under 12. A 50% DEET pocket spray sits at the high-concentration end of that range.
The third is consumer comfort. DEET at higher concentrations is well known to degrade certain plastics, irritate sensitive skin, and produce a residue some users find uncomfortable. Icaridin formulations are less aggressive on both fronts.
France is not breaking from any of this in regulatory terms. DEET is an approved active substance for repellent products in the EU biocides regime, and several European national agencies still endorse DEET at higher concentrations for travellers to tropical destinations. The French pharmacy shopper is making a reasonable choice. They are simply making it more decisively, and at a higher dose, than the average European pharmacy shopper currently does.
That divergence is the genuinely interesting market signal. The prominence of a 50% DEET spray in the 2026 results says: when the threat is local, when the species is named, and when the channel is the pharmacist, French consumers will reach past the gentler chemistry for the higher dose.
What This Means for the Wider Repellent Market
The market signal is worth reading plainly. Icaridin at 20% and a 50% DEET spray answer different questions: one is a general-use, family-friendly option, the other a high-concentration formulation for named, high-pressure exposure. Perceived threat level shapes which one a shopper reaches for, and as Aedes albopictus and locally transmitted chikungunya spread further across southern Europe, tolerance for higher-active formulations tends to rise with it.
For the public, the reading is plainer still. A 50% DEET formulation suits specific high-pressure situations: biting at dusk in Aedes albopictus-infested zones, fieldwork, or travel to dengue-endemic regions. It is more concentration than a routine evening in the garden calls for. The protection-time numbers are not free; the chemistry, however well-tolerated, is still a fairly powerful neuro-active compound applied to skin. Higher concentrations match higher-risk settings, while milder actives or physical barriers such as nets, screens and light clothing cover everyday, lower-risk exposure.
What we know
Sources Cited
- Insect Écran. Zones Infestées product page, 2026: https://www.insectecran.com/product/zones-infestees
- European Centre for Disease Prevention and Control. Aedes albopictus, Factsheet for experts and personal protective measures: https://www.ecdc.europa.eu/en/disease-vectors/facts/mosquito-factsheets/aedes-albopictus
- US EPA. Skin-Applied Repellent Ingredients: https://www.epa.gov/insect-repellents/skin-applied-repellent-ingredients
- Meilleurs Produits Pharma. Lauréats 2026: https://www.meilleurs-produits-pharma.com/laureats/2026/
- Coopération Pharmaceutique Française (Cooper). Legal notice: https://www.cooper.fr/mentions-legales
- Cooper. Insect Écran Zones Infestées product page: https://www.cooper.fr/insect-ecran-zones-infest%C3%A9es
- Service Public (Premier ministre). Présence du moustique tigre: https://www.service-public.gouv.fr/particuliers/actualites/A14140
- Santé publique France. Chikungunya, dengue et Zika en France hexagonale, bilan 2025: https://www.santepubliquefrance.fr/maladies-a-transmission-vectorielle/chikungunya/bulletin-national/chikungunya-dengue-et-zika-en-france-hexagonale-bilan-2025
- Santé publique France. Chikungunya, dengue et Zika en France hexagonale, bilan 2024: https://www.santepubliquefrance.fr/maladies-a-transmission-vectorielle/chikungunya/bulletin-national/chikungunya-dengue-et-zika-en-france-hexagonale-bilan-2024
- US Centers for Disease Control and Prevention. Preventing Mosquito Bites: https://www.cdc.gov/mosquitoes/prevention/index.html
- European Commission. Regulation on the supply and use of biocidal products (Regulation (EU) 528/2012): https://health.ec.europa.eu/biocides/regulation_en
- EUR-Lex. Commission Directive 2010/51/EU (DEET included in Annex I to Directive 98/8/EC for product-type 19, repellents and attractants): https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32010L0051
- ANSES. Which mosquito repellents can be used to protect children: https://www.anses.fr/en/content/which-mosquito-repellents-can-be-used-protect-children